ArticleBMC infectious diseases2025
Diagnostic accuracy and clinical impact of DNA microarray chip in pulmonary mycobacterial infections: a retrospective cohort study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundChina has a high burden of Mycobacterium tuberculosis (MTB), with increasing infections from non-tuberculous mycobacteria (NTM). Rapid and accurate identification is crucial for effective clinical management. This study aimed to evaluate the diagnostic performance of DNA microarray chip and identify risk factors associated to mycobacterial infections.
methodsBetween January 2021 and June 2023, 973 patients with presumptive mycobacterial infections were recruited from the First Affiliated Hospital of Guangzhou Medical University. Various detection methods were used for etiological diagnosis, and their performance was compared. Multivariable logistic regression analysis determined clinical risk factors for mycobacterial positivity.
resultsMycobacterial infection was confirmed in 438 patients, with 254 (58.0%) infected with MTB, 183 (41.8%) with NTM, and one co-infected with two. DNA microarray chip demonstrated the highest true positive rate (TPR) for mycobacterial detection at 96.8% and a true negative rate (TNR) of 90.8%. For MTB, the TPR was 94.5% with a TNR of 99.3%. Risk factors included cough/expectoration, pulmonary consolidation, cavitation, and bronchiectasis for mycobacterial infection, while smoking history and diabetes mellitus were independent risk factors for MTB infection.
conclusionsDNA microarray chip offers a sensitive and specific diagnostic approach for mycobacterial infections, potentially enhancing clinical diagnosis and informing targeted interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.